Ontology highlight
ABSTRACT:
SUBMITTER: Ray A
PROVIDER: S-EPMC5325451 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
Ray Abhijit A Williams Matthew A MA Meek Stephanie M SM Bowen Randy C RC Grossmann Kenneth F KF Andtbacka Robert H I RH Bowles Tawnya L TL Hyngstrom John R JR Leachman Sancy A SA Grossman Douglas D Bowen Glen M GM Holmen Sheri L SL VanBrocklin Matthew W MW Suneja Gita G Khong Hung T HT
Oncotarget 20160901 39
<h4>Purpose</h4>Intratumoral interleukin-2 (IL-2) is effective but does not generate systemic immunity. Intravenous ipilimumab produces durable clinical response in a minority of patients, with potentially severe toxicities. Circulating anti-tumor T cells activated by ipilimumab may differ greatly from tumor-infiltrating lymphocytes activated by intratumoral ipilimumab in phenotypes and functionality. The objective of this study was to primarily assess the safety of intratumoral ipilimumab/IL-2 ...[more]